6533b7d8fe1ef96bd126ad69

RESEARCH PRODUCT

High efficiency and clinical relevance of exome sequencing in the daily practice of neurogenetics

Arthur SorlinAntonio VitobelloBenoit DaubailChristel Thauvin-robinetMarie Hervieu-bègueLaurence FaivreAgnès FromontAnge-line BruelFrédéric Tran Mau-themThibault MoreauJulian DelanneGuy-victor OssebyQuentin ThomasPatrick CallierChristophe PhilippeSébastien MouttonMaurice GiroudAnne-sophie Denommé-pichonAgnès Jacquin-piquesSophie NambotYannis DuffourdPhilippine GarretY Béjot

subject

ProbandPediatricsmedicine.medical_specialtyMovement disordersNeurologyNeurodegeneration with brain iron accumulation[SDV]Life Sciences [q-bio]EncephalopathyNeurogenetics03 medical and health sciences0302 clinical medicineExome SequencingGeneticsHumansMedicineExomeClinical significance030212 general & internal medicineGenetic TestingGenetics (clinical)Exome sequencingComputingMilieux_MISCELLANEOUS030304 developmental biology0303 health sciencesbusiness.industrymedicine.diseasePhenotypeNeurology[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Neurology (clinical)Nervous System Diseasesmedicine.symptombusiness030217 neurology & neurosurgery

description

ObjectiveTo assess the efficiency and relevance of clinical exome sequencing (cES) as a first-tier or second-tier test for the diagnosis of progressive neurological disorders in the daily practice of Neurology and Genetic Departments.MethodsSixty-seven probands with various progressive neurological disorders (cerebellar ataxias, neuromuscular disorders, spastic paraplegias, movement disorders and individuals with complex phenotypes labelled ‘other’) were recruited over a 4-year period regardless of their age, gender, familial history and clinical framework. Individuals could have had prior genetic tests as long as it was not cES. cES was performed in a proband-only (60/67) or trio (7/67) strategy depending on available samples and was analysed with an in-house pipeline including software for CNV and mitochondrial-DNA variant detection.ResultsIn 29/67 individuals, cES identified clearly pathogenic variants leading to a 43% positive yield. When performed as a first-tier test, cES identified pathogenic variants for 53% of individuals (10/19). Difficult cases were solved including double diagnoses within a kindred or identification of a neurodegeneration with brain iron accumulation in a patient with encephalopathy of suspected mitochondrial origin.ConclusionThis study shows that cES is a powerful tool for the daily practice of neurogenetics offering an efficient (43%) and appropriate approach for clinically and genetically complex and heterogeneous disorders.

10.1016/j.jns.2021.117855https://hal.inrae.fr/hal-03463169